On June 24, AI pharmaceutical companyBioMapBioMap signed a strategic cooperation agreement with Hong Kong Investment Management Limited (HKIM), known as the "Hong Kong version of Temasek".
The Hong Kong Investment Company will provide resource matching and support for BioMap's development in Hong Kong, while BioMap will establish its first international innovation center (BioMap InnoHub) in Hong Kong and launch the accelerator program "BioMap BioX." It is expected that in the next five years, BioMap will support more than fifty cutting-edge life science early-stage R&D projects in Hong Kong through its large model platform. For the selected projects, BioMap will provide technical support utilizing the life science large model xTrimo and AIGP platform technology, aiming to enable the life science industry to start up and grow as rapidly as internet companies. BioMap CEO Robin Li Founded: Large Model + Life Science BioMap was founded in 2020 by Robin Li, CEO of Baidu, and Liu Wei, then CEO of Baidu Ventures. It is a large model company in the field of life science artificial intelligence. The core technology is a large foundational model in the life sciences centered on the language of proteins.xTrimoThe platform is the world's first and currently the largest ultra-large-scale multimodal model system in the field of life sciences.
The company further launched last yearAIGP(AI Generated Protein) Generative ProteinDesign platforms that specifically generate proteins or design proteins in a generative manner. So far, BioMap has signed up more than 200 users based on the AIGP platform, including international pharmaceutical companies, leading CDMOs, innovative drug companies, synthetic biology, green technology representative enterprises, and research institutions. Including the first life science large model cooperation in the pharmaceutical industry with Sanofi, with potential valueUltra10Billion USD。 "What's on the Mind of the 'Hong Kong Version of Temasek'?" BioMap is the second strategic partner announced by Gangtou Company within two weeks. The Hong Kong Investment Corporation, holding HKD 62 billion, is regarded by outsiders as the Hong Kong version of "Temasek".
Ms. Chen Jiaqi, CEO of Hong Kong Investment Management Co., Ltd. The company manages the HK$22 billion "Hong Kong Growth Portfolio," the HK$5 billion "Greater Bay Area Investment Fund," the HK$5 billion "Strategic Technology and Innovation Fund," and the HK$30 billion "Co-Investment Fund." The three locked themes are: Hard Technology, Life Science, and New Energy Technology, and BioMap meets the artificial intelligence (AI) hard technology standard. In July,On the list of partners of the port investment companyThere will be more companies related to life science and technology emerging. It is reported that the Hong Kong Investment Corporation will gradually layout in the fields of diagnostics, instruments, and pharmaceuticals, covering both "Western medicine and drugs" and "Traditional Chinese Medicine and drugs," with a focus on local, Greater Bay Area, and international markets. According to media reports, Hong Kong Investment Company will lead the new round of financing for BioMap, with the investment amount undisclosed. At the same time, Chen Jiaqi, CEO of Port Investment Company, said that the strategic cooperation between the two parties has four key focuses, includingBioMap will prioritize Hong Kong as the IPO listing location. —The End—
